Bibliography
- Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 2008;26:1201-3
- Ky B, Carver JR. Biomarker approach to the detection and cardioprotective strategies during anthracycline chemotherapy. Heart Fail Clin 2011;7:323-31
- Cardinale D, Colombo A, Lamantia G, Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-20
- Kumler I, Nielsen DL. Trials of bevacizumab in breast cancer-a safety review. Expert Opin Drug Saf 2011; Jun 11. [Epub ahead of print]
- Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011;305:487-94
- Dienstmann R, Ades F, Saini KS, Metzger-Filho O. Benefit-risk assessment of bevacizumab in the treatment of breast cancer. Drug Saf 2012;35(1):15-25
- Yip AY, Ong EY, Chow LW. Translational research to realize the full potential of novel agents – an opportunity for vinflunine? Expert Opin Drug Saf 2011;11(S1):5-8
- Culine S, Lucas S, Salhi Y, Bellmunt J. Updated survival results of the phase III trial comparing vinflunine (V) to best supportive care (BSC) in advanced transitional cell cancer of the urothelium (TCCU) after failure of a prior platinumcontaining regimen. Eur Urol Suppl 2010;9:38
- JAVLOR® Online Non-Interventional Trial (JONAS-1). The U.S. National Institutes of Health (NIH): ClinicalTrials.gov. Available from: clinicaltrials.gov/ct2/show/NCT01103544 [Last accessed 15 July 2011]
- Grothey A, Sugrue MM, Purdie DM, Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26(33):5326-34
- Gebbia V, Bellavia G, Ferraù F, Adherence, compliance and persistance to oral anti-neoplastic therapy: a review focused on chemotherapeutic and biologic agents. Expert Opin Drug Saf 2012;11(S1):49-59
- Hohneker J, Shah-Mehta S, Brandt PS. Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract 2011;7(1):65-7
- Rajpara AN, Feldman SR. Adherence to treatment: still the forgotten variable. Arch Dermatol 2010;146(10):1183-4